Nurami Medical is a clinical stage biotechnology company. Founded in 2014 by experts in nanofibers and biomaterials, Dr. Amir Bahar and Nora Nseir. Nurami is focused on the development of novel and functional biomaterials and nanofiber-based matrices for integration in its regenerative medicine solutions. The company develops innovative patches and sealants, which answer unmet needs and improve patient outcomes in various surgical procedures. Nurami Medical is ISO 13485 certified.
The company’s first product, ArtiFascia®, is a ground-breaking, multifunctional, nanofiber-based tissue reconstruction patch for neurosurgeries, combining a porous scaffold for tissue regeneration enhancement with a novel temperature-sensitive sealant, to prevent the entry of pathogens and CSF leaks. ArtiFascia® targets the $850 million dural grafts and sealant markets, which is poised to reach $1.4 billion in 2025.
Our vision is to revolutionize the field of regenerative medicine by developing application-specific, patches and surgical sealants using unique combinations of nanofibers and functional biomaterials.